GRI Bio shares surge 51.24% after-hours after positive Phase 2a IPF trial meets endpoints, shows fibrosis resolution and improved lung function biomarkers.

GRI Bio surged 51.24% in after-hours trading following the release of positive Phase 2a trial data for GRI-0621 in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint, demonstrating a favorable safety profile with no severe adverse events over 12 weeks. Key secondary endpoints showed improvements in biomarkers indicating fibrosis resolution and alveolar basement membrane repair, alongside a 39% increase in forced vital capacity (FVC) among treated subjects compared to 80% decline in the placebo group. The results highlight GRI-0621’s differentiated safety profile and disease-modifying potential, positioning it as a novel oral therapy for IPF, a condition with limited treatment options. The trial’s success, coupled with supportive statements from clinical experts and the company’s leadership, fueled the sharp post-announcement rally.